RainDance Technologies said this week that it has appointed Kathy Ordoñez to its board of directors.
Ordoñez has more than 30 years of experience in the life sciences and diagnostics industries. She previously served as senior vice president at Quest Diagnostics, which she joined following Quest's acquisition of Celera Corporation in 2011. Prior to this Ordoñez was CEO at Celera and a founder of Celera Diagnostics. Earlier in her career, Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as president and CEO and led the wide-scale commercial application of PCR to the research, diagnostic, and forensic fields.
Illumina said this week that it has named Tina Nova as senior vice president and general manager of its oncology business.
Nova will lead the company's strategy of enabling the oncology community to develop products for cancer management based on Illumina next-generation sequencing technologies. Previously, Nova co-founded Genoptix and served as its president and CEO. She was a member of the Genoptix board of directors until Novartis acquired the company in 2011. Nova also co-founded Nanogen and served as its chief operating officer and president from 1994 to 2000. Prior to Nanogen, Nova was COO of Selective Genetics and has held research and management positions with Ligand Pharmaceuticals and Hybritech, a former subsidiary of Eli Lilly. She holds a BS in biology from the University of California, Irvine and a PhD in biochemistry from UC Riverside.
Rick Klausner, who has served as interim oncology leader since January 2014, will continue in his role as Illumina's senior vice president and chief medical officer.